An Old TB Vaccine Finds New Life in Coronavirus Trials

Studies are underway to test whether giving a shot of BCG vaccine could protect doctors and nurses against COVID-19.

anthony king
| 8 min read
bcg tuberculosis tb sars-cov-2 covid-19 coronavirus pandemic vaccine nonspecific effects trained immunity innate immune system response

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

ABOVE: MODIFIED FROM © ISTOCK.COM, VISUAL GENERATION, FAIRYWONG, WENMEI ZHOU; © TASHA DIBIAGIO

One of the oldest vaccines could protect us against our newest infectious disease, COVID-19. The vaccine has been given to babies to protect them against tuberculosis for almost a century, but has been shown to shield them from other infections too, prompting scientists to investigate whether it can protect against the coronavirus.

This Bacille Calmette-Guérin (BCG) vaccine, named after two French microbiologists, consists of a live weakened strain of Mycobacterium bovis, a cousin of M. tuberculosis, the bacterium that causes tuberculosis. BCG has been given to more than 4 billion individuals, making it the most widely administered vaccine globally.

Because BCG protects babies against some viral infections in addition to TB, researchers decided to compare data from countries with and without mandatory BCG vaccination to see if immunization policies are linked to the number or severity of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • anthony king

    Anthony King

    Anthony King is a freelance science journalist based in Dublin, Ireland, who contributes to The Scientist. He reports on a variety of topics in chemical and biological sciences, as well as science policy and health. His articles have appeared in Nature, Science, Cell, Chemistry World, New Scientist, the Irish Times, EMBO Reports, Chemistry & Industry, and more. He is President of the Irish Science & Technology Journalists Association. 

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours